Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Status:
Completed

Trial end date:
2021-03-04

Target enrollment:

Participant gender:

Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.

Phase 2

Pfizer